Safety, recovery, and hospital resource use after robot-assisted pheochromocytoma resection in a 48-hour short-stay pathway: a single-center retrospective cohort study
In brief
A 48-hour pathway cut hospital stays and costs after robot-assisted pheochromocytoma surgery
In this single-center study of 110 patients, 93.6% of those assigned to a planned 48-hour pathway went home on target; they also had shorter stays, lower costs and opioid use, and higher recovery scores and satisfaction than conventional inpatients. Only two patients had a major safety event, so similar observed safety does not prove the approaches are equally safe; prospective validation is needed.
- Journal
- Journal of robotic surgery (Q1)
- Published
- 9 November 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Xinzhe Liu, Haoze Liu, Chuzhu Li, Jiwen Shang
- PMID
- 43002321
- DOI
- 10.1007/s11701-026-04179-7
Why clinicians should know about it
- Picked for Breast and Endocrine Surgery (paper of the day, 12 November 2026): Pheochromocytoma resection pathway informs adrenal operative care
Abstract
To compare perioperative safety, early recovery, and resource use between a short-stay pathway and conventional inpatient care for robot-assisted pheochromocytoma resection. This single-center retrospective cohort included 110 patients who underwent robot-assisted pheochromocytoma resection: 47 managed in a short-stay pathway with discharge planned within 48 h of hospital admission and 63 managed with conventional inpatient care during the same period. The primary outcome was a 30-day composite of Clavien-Dindo grade II or higher complications, unplanned intensive care, emergency attendance, readmission, reoperation, or death. Secondary outcomes included intraoperative hemodynamic instability, postoperative hypotension and hypoglycemia, pain, opioid consumption, Quality of Recovery-15 (QoR-15), length of stay, costs, pathway completion, and patient satisfaction. Welch t tests and Fisher exact tests were used for unadjusted comparisons, and absolute risk differences (RDs) and mean differences are reported with 95% confidence intervals (CIs). Exploratory linear models with heteroscedasticity-robust standard errors adjusted for age, sex, body mass index, ASA class, tumor size, and duration of alpha blockade; sensitivity analyses additionally adjusted for surgeon, surgical approach, secretory phenotype, and hypertension. Baseline, comorbidity, endocrine, and operative characteristics were similar between groups (all standardized mean differences < 0.30). The 30-day composite safety outcome occurred in 1 of 47 short-stay patients (2.1%) and 1 of 63 conventional inpatients (1.6%; RD 0.5% points, 95% CI -6.6 to 9.6; P = 1.000). Intraoperative hemodynamic instability was also similar (83.0% vs. 87.3%; P = 0.590), as were persistent postoperative hypotension (8.5% vs. 7.9%) and postoperative hypoglycemia (8.5% vs. 7.9%). The planned 48-hour discharge target was achieved in 44 of 47 patients (93.6%). Compared with conventional care, the short-stay pathway had lower 24-hour pain scores (mean 1.8 vs. 2.4), total inpatient opioid exposure (8.7 vs. 17.7 mg morphine milligram equivalents), postoperative stay (44.2 vs. 105.1 h), total stay (49.2 vs. 476.4 h), and total in-hospital cost (CNY 49,858 vs. CNY 64,802), with higher 24-hour QoR-15 (119.7 vs. 107.9) and satisfaction (9.2 vs. 8.2); these differences remained significant after Holm correction and were consistent in fully adjusted sensitivity analyses. Among selected patients undergoing robot-assisted pheochromocytoma resection, the short-stay pathway was associated with similar observed perioperative safety outcomes, faster recovery, shorter hospitalization, lower in-hospital costs, and higher patient satisfaction than conventional inpatient care. Because only two composite events occurred and the 95% CI of the risk difference was wide, these findings provide preliminary evidence of feasibility rather than proof of equivalent safety, and support prospective validation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.